Gynecologic cancers present a significant health problem for women in the United States with 81 800 new cases and 26 500 deaths estimated for 1997 (1) . Cervical, endometrial, and ovarian cancers represent most of these cases. While many cases of cervical and endometrial cancers are detected early when the disease is curable, advanced cases of these diseases still occur, and they remain essentially incurable despite improvements in chemotherapy and radiotherapy. Ovarian cancer is associated with an extremely high case-fatality rate because most cases are diagnosed only when the disease is at a late stage. This cancer accounts for more than half of all the gynecologic cancerassociated deaths (14 200 estimated deaths for 1997) in the United States (1) . Thus, intense efforts have recently focused on elucidating the molecular mechanisms involved in these diseases.
Recently, the retinoids have generated substantial interest as potential therapeutic and preventive agents for the treatment of cancer [reviewed in (2) (3) (4) ]. Studies have reported the antileukemic effects of all-trans-retinoic acid in patients with acute promyelocytic leukemia (5) and also chemopreventive effects of isoretinoin (13-cis-retinoic acid) in reducing the number of second primary tumors in patients with prior squamous cell carcinoma of the head and neck (6) . Although these agents have demonstrated therapeutic effectiveness, toxicity associated with the natural retinoids frequently limits their use. This has led to the development of synthetic vitamin A analogues that are currently being tested to evaluate their clinical effectiveness (3, 4) .
Of these synthetic analogues, N-(4-hydroxyphenyl) retinamide (4HPR or fenretinide) has emerged as one of the most promising alternatives to the natural retinoids. At pharmacologically achievable levels, 4HPR inhibits the growth of human cancer cell lines in culture, including small-cell lung cancer (7) , malignant hemopoietic cells (8) , and breast cancer cells (9, 10) . This agent is also effective in reducing tumor load in animal model systems (11) (12) (13) . Although it has been reported that the antiproliferative effects of 4HPR in cultured cancer cell lines are mediated through the induction of apoptosis (7, 8, 14, 15) , the mechanism of action of 4HPR remains poorly understood.
Preliminary results of a recent clinical trial showed that 4HPR effectively prevented the development of second primary cancers in a group of patients with localized breast cancer (16) . Evidence from this study also suggested that 4HPR may protect women against the development of ovarian cancer (17, 18) . The reported growth-inhibitory effects of 4HPR on a wide range of cancer cell lines and the preliminary clinical effectiveness of this drug identifies 4HPR as an ideal potential candidate for evaluation in the treatment of gynecologic cancers. Characterizing the biologic effects of 4HPR and its mode of action may allow us to design more effective treatment and prevention strategies for these tumors. In this study, we examined the antiproliferative effects of 4HPR in a range of gynecologic cancer cell lines and evaluated the role of the retinoid receptors in modulating the effects of 4HPR.
Materials and Methods

Cell Culture
The cell lines AD10, UCI 101, UCI 107, SKOV3, and 222 were provided by Dr. G. Scott Rose, University of California, Irvine, CA; CP70 was obtained from Dr. E. Reed, National Cancer Institute, Bethesda, MD; ML3B (cystadenofibroma) and ML5 (serous cystadenoma) were obtained from Dr. Louis Dubeau, Norris Cancer Center, University of California, Los Angeles; and A224 was obtained from Dr. J. De Greve, Oncologisch Centrum, Brussels, Belgium. All cell lines were propagated using cell culture techniques described previously (19) . Briefly, the ovarian cancer cell lines A224, AD10, UCI 101, UCI 107, SKOV3, 222, and CP70 were propagated in RPMI-1640 medium; immortalized ovarian cell lines, ML3B (cystadenofibroma) and ML5 (serous cystadenoma) cells, both of which were immortalized after modification with an adenoviral vector expressing SV40 large T antigen, were grown in Dulbecco's minimum Eagle medium; the cervical cancer cell lines HT3 and ME180 were propagated in McCoy's 5A medium; and the endometrial cancer cell line Hec 1A was propagated in McCoy's 5A medium. All media were supplemented with 10% fetal calf serum (FCS), 20 mM glutamine, 100 U/mL penicillin G, and 100 mg/mL streptomycin sulfate. All tissue culture reagents were obtained from Life Technologies Inc. (GIBCO BRL), Gaithersburg, MD.
4HPR (provided by R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ) was reconstituted in absolute ethanol to a concentration of 1 mM, and the stock solution was stored under light-free conditions at −20°C. All experiments using 4HPR were performed under yellow light.
Plasmids
Expression plasmids containing the human retinoic acid receptor (hRAR) ␣, ␤, and ␥ complementary DNA (cDNA) sequences were from Dr. Mack Mabry, The Johns Hopkins Oncology Center, Baltimore, MD; and the murine retinoic X receptor (RXR) ␣, ␤, and ␥ cDNA sequences were from Dr. Ron Evans, Salk Institute for Biological Studies, La Jolla, CA.
Growth Assays
Cells were plated at 25% confluency in 96-well microtiter plates and 1 M 4HPR was added 24 hours later. Cell growth was measured at 24-hour intervals by use of a MTT (dimethyl thiozolyl-2Ј,5Ј-diphenyl-2-H-tetrazolium bromide)-based cell proliferation assay (Non Radioactive Cell Proliferation Assay, Promega Corp., Madison, WI); optical densities were measured at a wavelength of 570 nm after a 4-hour incubation with indicator dye. The IC 50 concentration (i.e., that necessary to yield a 50% inhibition of measured growth) of 4HPR was determined by adding 4HPR over a range of concentrations to cells plated at 25% confluency in 96-well microtiter plates in growth media supplemented with 5% FCS. Cells were incubated for 5 days and the number of viable cells was determined by the cell proliferation assay described above. Each data point represents the mean value (and 95% confidence interval [CI]) calculated from eight wells in one experiment. All experiments were done at least two times.
Northern Blot Analysis
Total RNA was isolated from subconfluent cells as previously described (20) . Ten-milligram RNA samples were electrophoresed through 1% agarose gels containing formaldehyde and were transferred to nitrocellulose membranes as previously described (20) . Blots were incubated with the indicated [ 32 P]deoxycytosine triphosphate-labeled human RAR␣, RAR␤, and RAR␥ or murine RXR␣, RXR␤, and RXR␥ cDNA probe, washed, and exposed to XAR film (Kodak, Rochester, NY). Signals were quantitated using a densitometer (Molecular Dynamics, Sunnyvale, CA). To normalize for differences in RNA loading, all signals were adjusted based on the signal from the corresponding 28S ribosomal RNA band as visualized by ethidium staining and UV illumination.
DNA Fragmentation Assay
Cells were plated at 25% confluency in 100-mm dishes in media supplemented with 5% FCS; 24 hours later, they were exposed to 4HPR. Combined adherent and nonadherent cells were harvested at 56 hours and incubated in 0.4 mL proteinase K solution (10 mM Tris [pH 7.4], 10 mM EDTA, 150 mM NaCl, 0.4% sodium dodecyl sulfate, and 1 mg/mL proteinase K [Life Technologies, Inc.]) at 65°C for 15 minutes and overnight at 37°C. Deoxyribonuclease-free ribonuclease A (Sigma Chemical Co., St. Louis, MO; 10 mg/mL) was added after a phenol-chloroform extraction and extraction was repeated. DNA was precipitated, resuspended, and electrophoresed through a 1.5% agarose gel containing Tris-acetate/EDTA electrophoresis buffer.
Anchorage-Independent Growth
Low-temperature gelling agarose (Sea Plaque, FMC Corp., Rockland, ME) was sterilized and diluted to a concentration of 0.7% in RPMI-1640 medium supplemented with 10% FCS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 20 mM glutamine. Cells (1 × 10 4 ) were resuspended in 6 mL of 0.35% agarose and plated over a prehardened feeder layer of 0.7% agarose. Culture dishes were placed at 4°C to solidify the agarose and were transferred to a humid 37°C incubator supplemented with 5% CO 2 . Colonies were scored manually on day 14 by microscopic evaluation under 100× magnification with cloning efficiency reported as a percentage of the cell number initially plated.
Transfection
Human RAR␤ cDNA was blunt-ligated into the Pvu II restriction site of the episomal expression vector pCEP4b with transcription expression under the control of the cytomegalovirus (CMV) promoter and transfected into the AD10 ovarian carcinoma cell line by use of the calcium phosphate precipitation technique as previously described (21) . Transfected cells were selected on the basis of hygromycin resistance and multiple clones were pooled. Transfected cells were propagated in RPMI-1640 medium containing 0.25 mM hygromycin.
Statistical Analysis
All values shown represent the mean with either standard deviation or 95% CI indicated. The Student's t test was performed to estimate the statistical significance of differences. All P values resulted from use of two-sided statistical tests.
Results
Biologic Effects of 4HPR on Gynecologic Cancer Cell Lines
The effect of 4HPR on seven ovarian, two cervical, and one endometrial cancer cell lines and on two immortalized ovarian epithelial cell lines was tested by measuring cellular proliferation in the presence of 1 M 4HPR over 120 hours (Fig. 1 ). This concentration of 4HPR significantly inhibited growth of three ovarian cancer cell lines; at 96 hours, growth of the cell lines 222, CP70, and UCI 101 was inhibited 83%, 70%, and 37%, respectively (all P<.0001; Student's t test); however, this concentration of 4HPR failed to inhibit growth of the other cell lines tested ( Fig. 1, B) . Measurement of the IC 50 of 4HPR for all the cell lines indicated that 222, UCI 101, and CP70 were most sensitive to inhibition of growth by 4HPR, with IC 50 levels of 0.3, 0.4, and 1.2 M, respectively ( Table 1 ). The other cell lines were also sensitive to growth inhibition by 4HPR, but at higher drug concentrations (IC 50 values ജ3 M) ( Table 1) .
The ability of cells to grow in soft agar provides a measure of tumorigenic potential. Three cell lines, 222, AD10, and UCI 107, which display a wide range in sensitivity to 4HPR (IC 50 , respectively), were tested for anchorage-independent growth in the absence or presence of a range of 4HPR concentrations. At 5 M 4HPR, anchorage-independent growth was inhibited by 68% (P ‫ס‬ .00028, Student's t test) for AD10 (relative to cells grown in the absence of 4HPR), while it had no effect on the anchorageindependent growth of UCI 107 cells. Cell line 222 did not clone (Fig. 2) .
Close examination of adherent cells treated with inhibitory concentrations of 4HPR revealed cellular morphology suggestive of apoptosis (data not shown). To formally determine if apoptosis was the mechanism of adherent growth inhibition by 4HPR, we analyzed several cell lines in the absence or presence of 4HPR for the DNA fragmentation pattern associated with apoptosis. Fig. 3 demonstrates that cells of most of the tested lines displayed DNA fragmentation patterns consistent with apoptosis after exposure to 4HPR for 56 hours at concentrations close to the respective IC 50 doses. A224 cells exhibited minimal apoptosis at the concentrations of 4HPR that were tested; this result was consistent with the high IC 50 determined for this cell line.
RAR and RXR Expression in Cell Lines Treated With 4HPR
Northern blot analysis was performed on a subset of the cell lines to determine if sensitivity to 4HPR was associated with retinoid receptor (RAR and RXR) expression. Ovarian cancer cell lines that spanned the spectrum from sensitive (222, UCI 101, and CP70) to resistant (AD10 and A224), and representative cervical (ME180, resistant to 4HPR) and endometrial (Hec 1A, resistant to 4HPR) cancer cell lines were incubated in the ab- . Cells were plated at 25% confluency in microtiter plates in the presence or absence of 1 M 4HPR, and cell proliferation was measured by the MTT (tetrazoliumbased colorimetric) assay every 24 hours. These assays were performed in the presence of 10% fetal calf serum (FCS) for all cell lines except for CP70, which was grown in the presence of 2% FCS. Other ovarian cancer cell lines tested include: SKOV3, A224, and UCI 107, which were resistant to growth inhibition at this concentration of 4HPR (data not shown). * ‫ס‬ P<.0001, Student's t test (two-tailed). Error bars ‫ס‬ 95% confidence intervals. B) Growth inhibition of ovarian, cervical, and endometrial cell lines incubated with 1 M 4HPR. Cell proliferation, in the absence or presence of 4HPR, was measured by MTT assay at 96 hours, at which time growth inhibition was maximal in all sensitive cell lines. Error bars ‫ס‬ 95% confidence intervals.
sence or presence of 4HPR (equivalent to the IC 50 dose for each cell line) for 96 hours and RNA was isolated for the determination of RAR (␣, ␤, and ␥) and RXR (␣, ␤, and ␥) expression levels. Arrows in Fig. 4 indicate the 3.8-kilobase (kb) and 2.8-kb transcripts for RAR␣, 3.4-kb and 2.9-kb transcripts for RAR␤, 3.3-kb and 3.1-kb transcripts for RAR␥, and the single bands for the various RXR transcripts.
Baseline expression levels of RAR (␣, ␤, and ␥) varied between the cell lines tested (Fig. 4 and Table 2 ). However, there was no statistically significant difference in basal expression of RAR␣ (P ‫ס‬ 1.0; Student's t test) or RAR␥ (P ‫ס‬ .82; Student's t test), based on densitometry normalized to the ethidium bromide-stained 28S ribosomal RNA band, in cells sensitive to 4HPR (222, UCI 101, and CP70; all with IC 50 <3 M) compared with less sensitive (i.e., resistant) cell lines (AD10, A224, ME180, and Hec 1A; all with IC 50 ജ3 M). In addition, 4HPR *IC 50 for N-(4-hydroxyphenyl) retinamide (4HPR) (M) was determined for ovarian, cervical, and endometrial cancer cell lines and immortalized ovarian cell lines as described in the ''Materials and Methods'' section. IC 50 was determined for cells growing in media containing 5% fetal bovine serum and is shown with 95% confidence intervals (CIs). induced RAR␣ and RAR␥ transcript levels in some cell lines, but there was no statistically significant difference in induced RAR ␣ and ␥ transcript levels in cells of the three 4HPR-sensitive lines versus cells of the four resistant lines (P ‫ס‬ .84 and P ‫ס‬ .71, respectively; Student's t test). The basal levels of RAR␤ in cells sensitive to 4HPR (222, UC101, and CP70) were not significantly different (P ‫ס‬ .301; Student's t test) from the basal RAR␤ transcript levels measured in less sensitive cells (AD10, A224, ME180, and Hec 1A). However, following 4HPR treatment, RAR␤ messenger RNA (mRNA) levels were elevated in all three sensitive cell lines but in only one of four resistant cell lines ( Table 2) . As a result, induced levels of RAR␤ transcripts in cells of the three 4HPR-sensitive lines were significantly higher (2.8-fold; P ‫ס‬ .006; Student's t test) than in cells of the four resistant lines. These results suggest that the relatively high levels of RAR␤ expression in ovarian cancer cell lines are related to the sensitivity of cells to the growthinhibitory effects of 4HPR.
In contrast, there was no difference in expression of the RXR transcripts in 4HPR-sensitive cells versus less sensitive cells. In the absence of 4HPR, similar levels of RXR␣ and RXR␤ transcripts were observed in 4HPR-sensitive (222, UCI 101, and CP70 [as above]) and 4HPR-resistant (AD10, A224, ME180, and Hec 1A [as above]) cells. Expression of RXR␥ mRNA varied among cell lines, but there was no difference in induced expression of RAR␥ in 4HPR-sensitive and -insensitive cells. We observed that treatment of the cells with 4HPR-induced RXR␤ expression in A224 and Hec 1A cells and RXR␥ expression in 222, UCI 101, and A224 cells (Fig. 4 and Table 2 ). The pattern of RXR␤ and RXR␥ induction in these cell lines did not correspond to inhibition of growth by 4HPR.
Exogenous Expression of RAR␤ and the Effects on 4HPR Sensitivity
To further examine the relationship between the inhibitory effects of 4HPR on cell proliferation and RAR␤ expression levels, we stably over-expressed RAR␤ in AD10 cells. RAR␤ transcripts were not detected in the AD10 cell line (Fig. 4) . We transfected the RAR␤ gene under the control of a CMV promoter in an episomal plasmid into AD10 cells and isolated pools of clones expressing various levels of RAR␤ transcripts (pooled cell clones 1-1␤, 1-3␤, 1-4␤, and 1-5␤). Cells were transfected with vector alone (3-1 cells) for use as a control cell line. Densitometric analysis of the northern blot autoradiogram indicated the following relative expression of RAR␤ in the pools of clones isolated: 1, 100, 62, and 15 for transfectants 1-1␤, 1-3␤, 1-4␤, and 1-5␤, respectively, all relative to 1-1␤ (normalized to the 28S ribosomal RNA band). AD10 cells, expressing high (cell clones 1-3␤ and 1-4␤) levels of exogenous RAR␤ transcripts, displayed a moderate increase in sensitivity to 4HPR in monolayer culture relative to the control pool of 3-1 cells (P<.0001; Student's t test) (Fig. 5, A) .
Transfection of AD10 cells with RAR␤ substantially impacted on the sensitivity of AD10 cells to 4HPR in the soft-agar cloning assay. AD10 transfectants expressing low levels of exogenous RAR␤ transcripts (cell clones 1-1␤ and 1-5␤) displayed intermediate sensitivities to 4HPR in a soft-agar cloning assay, unlike the control 3-1 cells. 4HPR (1 M) reduced anchorage-independent growth (in the absence of 4HPR) for transfectant pool 1-5␤ by 85% (P ‫ס‬ .00014; Student's t test) (Fig. 5, B) . Transfectant pool 1-1␤ (with RAR␤ transcript expression 15-fold lower than pool 1-5␤) exhibited a 16% reduction (not statistically significant; P ‫ס‬ .28; Student's t test) of anchorage-independent growth when treated with 1 M 4HPR (Fig. 5, B) . Further evidence supporting an association between the sensitivity of anchorage-independent growth of RAR␤ transfectants to 4HPR and the level of exogenous RAR␤ expression was observed when the RAR␤ transfectants were cultured to late passage. Northern blot analysis demonstrated that late passage transfectants grown in the presence or absence of hygromycin expressed lower levels of exogenous RAR␤ transcripts compared with early-passage transfectants for the same pool of cells. Densitometric analysis of the northern blot autoradiogram indicated the following relative expression of RAR␤ in the pools of cell clones: 100, 53, and 12 for transfectants 1-3 ␤P4 (passage 4), 1-3 ␤P14 (passage 14), and 1-3 ␤P15 (passage 15) in no hygromycin, respectively, all relative to cell clone 1-3 ␤P4 (normalized to the 28S ribosomal RNA band). This reduction in RAR␤ expression was associated with elevated levels of anchorage-independent growth for transfectant 1-3␤ (Fig. 6, A) . Anchorage-independent growth of 1-3 ␤P14 and 1-3 ␤P15 (late passages) were eightfold and 31-fold higher at 0.001 M 4HPR, respectively, than 1-3 ␤P4 (early passage) (P ‫ס‬ .000014 and P ‫ס‬ .009, respectively; Student's t test).
In addition, AD10 transfectants expressing high levels of ex- *The relative RAR and retinoid X receptor (RXR) messenger RNA (mRNA) expression is shown from a single representative experiment. Numbers refer to fold up-regulation of receptor mRNA in the presence of an IC 50 concentration of 4HPR. +, ++, and +++ ‫ס‬ 1x, 2x, and 3x, respectively, relative basal-specific receptor expression levels (normalized to 28s ribonsomal RNA), ‫ס-‬ receptor mRNA expression not detected at baseline, nd ‫ס‬ not done, 0 ‫ס‬ receptor mRNA expression is not induced over baseline.
ogenous RAR␤ transcripts (pooled cell clones 1-3␤ and 1-4␤) displayed no anchorage-independent growth in the presence or absence of 4HPR. The complete lack of anchorage-independent growth of the early-passage pools of cell clone 1-3␤ in the absence of 4HPR (Figs. 5, B and 6 , A) could be due to the presence of retinoids in the serum component of the culture medium. To examine this issue, cells (transfectant clone 1-3␤) were plated in soft agar with medium containing charcoalstripped serum or untreated serum. The results in Fig. 6 , B, demonstrate that the cell clone 1-3␤ displayed higher levels of anchorage-independent growth in medium containing charcoalstripped serum than untreated serum. These results suggest that the presence of retinoids in the serum of the culture medium could be responsible for the complete absence of anchorageindependent growth of transfectants expressing high levels of RAR␤, despite the absence of 4HPR.
Discussion
There is accumulating evidence of an important role for abnormal retinoid signaling in the development of many epithelial cancers. Retinoids appear to be critical in the normal develop- ment and maintenance of many epithelial tissues and epidemiologic data support an inverse relationship between vitamin A levels and the incidence of cancers such as lung cancer (22) . Studies (2, 23, 24) have identified abnormal expression of retinoid receptors in various cancers strengthening the suggestion that these genes are important in the development of these human cancers. The retinoid receptor most often involved is RAR␤, which has been found to be abnormally expressed in lung (23) and head and neck (24) cancers. This article demonstrates that a subset of ovarian cancer cell lines, but not the other tested gynecologic cancer cell lines, has low levels of or no RAR␤ mRNA expression (even when treated with 4HPR). These cell lines are relatively resistant to 4HPR-induced apoptosis, and re-expression of RAR␤ increases the sensitivity of the cells to 4HPR. These data suggest that RAR␤ expression may play a role in the development of ovarian cancer, that 4HPR may be an important new agent for the treatment or prevention of this disease, and that RAR␤ may modulate the inhibitory effect of 4HPR.
The growth-inhibitory effects of 4HPR demonstrated in this study are important for several reasons. First, the growth curves demonstrated an inhibitory activity of 4HPR at pharmacologically achievable concentrations for most of the cell lines (1-2 M). A previous pharmacokinetic study has demonstrated that this concentration of 4HPR is achievable with oral administration of the drug (16) . Second, there appears to be a ''therapeutic'' window between the concentration at which a subset of ovarian cancer cell lines were inhibited and the ''normal'' ovarian cells were not. Previous characterization of the effects of 4HPR on ovarian cancer cells has not included ''normal'' control cells (14) . This difference in inhibitory concentration is important for the potential therapeutic use of 4HPR and particularly its use as a chemoprevention agent. Third, the biologic effects of 4HPR described in this article includes inhibition of anchorage-independent growth at concentrations that are considerably lower than the inhibition of cell growth (0.1-1 M). Since anchorage-independent growth is generally considered a measure of malignant cell growth, its inhibition at these low concentrations of 4HPR suggests that 4HPR might be a particularly active agent for suppressing the malignant features of these cell lines.
The 4HPR growth inhibition of ovarian cancer cell lines appears to be, in part, the result of the induction of programmed cell death. 4HPR induction of apoptosis has previously been observed for several different cancer cell lines, including smallcell lung cancer cells (7), breast cancer cell lines (9), prostate cancer cell lines (25) , and ovarian carcinoma cells (14) . However, other mechanisms of growth inhibition have also been described. In particular, the inhibition of cell growth caused by 4HPR treatment in esophageal squamous carcinoma cell lines was associated with morphologic alterations consistent with differentiation and not apoptosis (26) . Recent evidence suggests that both all-trans-retinoic acid and 13-cis-retinoic acid exerted an antiproliferative effect in breast cancer cell lines either through the induction of apoptosis or differentiation, and that the effect was cell-line specific (27) . This difference in biologic end points most likely reflects differences in the intracellular milieu of the various cell lines tested. While programmed cell death is clearly important for 4HPR-induced growth inhibition in the ovarian cancer cell lines we tested, we cannot exclude that 4HPR also induced cellular differentiation, despite the absence of gross morphologic changes.
The exact molecular mechanism underlying the effects of 4HPR remains unknown, with conflicting reports regarding the role of the retinoid receptors in this process. A recent study (15) proposed that 4HPR induced apoptosis in cervical carcinoma cells in a retinoid receptor-independent pathway involving reactive oxygen species. Pellegrini et al. (9) concluded that 4HPR inhibited breast cancer cell growth, regardless of RAR status. In fact, a close examination of their data suggests that sensitivity of breast cancer cell lines to 4HPR correlates inversely with RAR␤ expression levels (9) . Direct biochemical studies to quantitate the binding of 4HPR to the RARs demonstrated minimal levels of 4HPR binding to these receptors (10) . The same authors also reported that 4HPR only minimally activated the retinoic acid and retinoid X response elements in human breast carcinoma cells. In contrast, Fanjul et al. (28) demonstrated that 4HPR induced transactivation with RAR␥ and RAR␤ but not RAR␣ or RXR␣. Unfortunately, since these latter studies were conducted in transiently transfected cells, the apparent impact of 4HPR on transactivation could reflect indirect effects of this drug on endogenous retinoid ligands. The results of a similar study by Kazmi et al. (29) reported that all-trans-retinoic acid was 100-fold more effective than 4HPR in inducing transactivation. The role of the retinoid receptors in modulating the effects of 4HPR in ovarian cancer cell lines is similarly uncertain. Results from a study by Supino et al. (14) suggested that RAR␤ expression correlated with sensitivity to the growth-inhibitory effects of 4HPR, although this correlation was based on one cell line. In addition, the same authors observed alterations in RAR␣ and RAR␥ expression and suggested these as potential modulators of 4HPR activity. A consistent problem with all of these studies is that RAR␤ expression was examined only at baseline and not after 4HPR treatment. While this might at first seem to make sense, since there are little data suggesting that 4HPR interacts with or induces retinoid receptors, our results demonstrate that in certain cell lines, RAR␤ expression is induced by 4HPR. When this induction is taken into consideration, this study demonstrates that cells sensitive to the growth-inhibitory effects of 4HPR expressed higher levels of RAR␤ than more resistant cell lines, suggesting the involvement of RAR␤ in modulating the effects of 4HPR. This observation may have clinical importance, since treatment of patients with all-trans-retinoic acid for head and neck cancer caused an induction of RAR ␣, ␤, and ␥ transcript expression (30) . In patients with oral premalignant lesions, treatment with all-trans-retinoic acid up-regulated RAR␤ expression (31) .
More direct evidence for a modulating role for RAR␤ in 4HPR growth inhibition is provided by our transfection studies. Expression of RAR␤ in ovarian cancer cells that lacked RAR␤ expression resulted in suppression of anchorage-independent growth. The suppression of anchorage-independent growth paralleled the RAR␤ expression levels in all independent pools of clones isolated. In addition, the suppression of anchorageindependent growth decreased over time as the pools of clones were passaged, reflecting reduced levels of exogenous RAR␤ expression. Of note, RAR␤ expression inhibited cloning even in the absence of 4HPR. This has been observed before in lung cancer cells and thought to be related to the presence of retinoids in the tissue culture media (32) . We tested this hypothesis by growing the RAR␤-expressing clones in soft agar containing charcoal-stripped serum and found anchorage-independent growth increased (despite the removal by charcoal of many growth factors and other substances that generally help cells grow in soft agar). This strongly suggests that retinoids in the serum were binding to the overexpressed RAR␤ in these cells and inhibiting their cloning. Of interest, overexpression of RAR␤ had only a moderate effect on cellular proliferation as measured by MTT assay. It is generally accepted that the two assays (cell growth and anchorage-independent growth) measure different cellular processes. The biologic processes necessary for anchorage-independent growth may be more sensitive to elevated levels of RAR␤ than the processes operating in adherent growth. In addition, it is possible that the RAR␤ transcript levels may not accurately reflect receptor protein levels. The amount of RAR protein produced by the exogenous gene may be lower than that produced from the endogenous gene. The growth curves for the AD10 RAR␤ transfectant demonstrate a moderate inhibition of adherent cell growth. This inhibition, while small, most likely accounts for the loss of exogenous RAR␤ expression over time in culture in the transfectants. Thus, there may be important quantitative differences between the amount of RAR␤ expression and inhibition of adherent versus anchorageindependent growth.
Gynecologic cancers remain a significant health problem for women in the United States. In particular, the high mortality rate associated with ovarian cancer underscores the need to develop more effective approaches to combat this disease. The data presented here suggest that 4HPR is an effective agent in inducing apoptosis in a number of ovarian cancer cell lines. Modulation of this apoptosis can be achieved by alteration of RAR␤ expression. Confirmation of the clinical ultility of 4HPR will need to await prospective clinical trials.
